Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report issued on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, Maxim Group raised Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research note on Thursday, July 11th.

Brainstorm Cell Therapeutics Stock Performance

Brainstorm Cell Therapeutics stock opened at $0.26 on Friday. The firm has a market cap of $18.05 million, a P/E ratio of -0.80 and a beta of 0.37. The business’s fifty day moving average is $0.33 and its two-hundred day moving average is $0.42. Brainstorm Cell Therapeutics has a 52 week low of $0.13 and a 52 week high of $1.58.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). During the same period last year, the business posted ($0.27) earnings per share. On average, equities research analysts predict that Brainstorm Cell Therapeutics will post -0.19 earnings per share for the current year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.